Dr Agarwal's HealthCare Limited IPO GMP Price Date Details

Dr Agarwal's Health Care Limited IPO GMP Price Date Details

Dr Agarwal's HealthCare Limited : Company Overview

Foundation and History

In 2010 Dr. Agarwal’s Health care Ltd. started in chennai which is now its Headquarters. It was actually started by Dr. TS Agarwal with a small eye hospital is now one of the leading Eyecare centers. Over many years as an organization it has transformed to become India’s top eye care provider through its provision of advanced ophthalmic treatments both at home and overseas markets.

Core Business and Services

The company delivers complete eye care solutions which treat various types of patients. Its services include:

  • Cataract Surgery:There are two main and modern cataract surgeries are offered at the centres with  phacoemulsification and laser-assisted cataract surgery.

  • Refractive Surgery: Dr. Agarwal’s Health care Ltd. also provides LASIK and other laser correction treatments for vision problems.

  • Retina Services: Treatment for diabetic retinopathy, macular degeneration, and other retinal disorders are one of the major and best services provided by the organization.

  • Cornea Care: Keratoplasty and corneal transplant surgeries.

  • Glaucoma Treatment: Early detection, medical management, and surgical options.

  • Pediatric Ophthalmology: Pediatric eye rehabilitation programs which help patients with vision problems and alignment issues constitute the services included under eye care.

  • Optical Services: The services offer optical products alongside contact lenses and eyeglasses as well as eye care pharmaceutical products.

Global Presence

Dr Agarwal’s Health care Limited has developed its healthcare facilities outside of India. More than 150 centers lie within the company’s global network which reaches across 11 countries while maintaining facilities in Africa and Southeast Asia. Through its international network expansion the clinic continues to position itself as a world-leading ophthalmology organization.

Technological Innovation

The business organization adopts leading technological advances as part of its fundamental operational principle. Through femtosecond laser technology and sophisticated retinal imaging systems Dr. Agarwal’s Health care Limited continues to lead ophthalmic innovation practices. Dr. Agarwal’s Health care Limited became the first medical organization in India to introduce both micro phaco cataract surgery as well as advanced LASIK procedures.

Patient Centric Approach

Dr Agarwal’s Health care limited delivers attentive patient care along with high standards of medical service excellence. The healthcare facility works to extend eye care accessibility across every socioeconomic group while maintaining premium-grade and budget-friendly clinical services. Through their individualized care practices Dr. Agarwal’s Health care Limited  matches appropriate treatments to each patient’s unique medical requirements.

Awards and Accolades

Several national and international awards have recognized the company’s exceptional eye care services including innovation awards and patient satisfaction awards together with industry contribution awards.

Vision and Mission

Vision: The organization aims to become the worldwide leader for trusted eye care services.

Mission: Eye care services of the highest quality will reach each person through the integration of innovative expertise.

Dr Agarwal’s Health care Limited IPO

Dr Agarwal’s Health care Limited will allow subscription of their IPO from January 29, 2025 through its scheduled close date of January 31, 2025. The issued equity shares will trade within the range of ₹382 to ₹402 each. Existing shareholders together with promoters plan to acquire up to 6,78,42,284 equity shares through an offer-for-sale (OFS) as the company intends to raise around ₹3,027.26 crore using fresh company shares worth ₹300 crore alongside this OPS arrangement. New investors must buy a minimum of 35 individual post-investment share types when executing multiple share types through their bids. The allocation plan allocates 50% to qualified institutional buyers (QIBs) alongside 15% to non-institutional investors (NIIs) and the remaining 35% to retail investors.

Dr Agarwal’s Health care IPO Details

  • IPO Open Date: January 29, 2025

  • IPO Close Date: January 31, 2025

  • Price Band: ₹382 to ₹402 per equity share

  • Lot Size: 35 shares per lot and in multiples thereof

  • IPO Size: Approx. ₹3,027.26 crore

  • Fresh Issue: ₹300 crore

  • Offer for Sale (OFS): Up to 6,78,42,284 equity shares by existing shareholders and promoters

Dr Agarwal’s Health care Limited IPO Dates

  • IPO Opening Date: January 29, 2025

  • IPO Closing Date: January 31, 2025

  • Finalization of Allotment: February 3, 2025

  • Initiation of Refunds: February 4, 2025

  • Credit of Shares to Demat Accounts: February 4, 2025

  • Listing Date: February 5, 2025

Investor Allocation

  • Qualified Institutional Buyers (QIBs): Up to 50% of the offering

  • Non-Institutional Investors (NIIs): At least 15% of the offering

  • Retail Investors: Minimum 35% of the offering

Utilization of IPO Funds

The net proceeds from the fresh issue are intended to be utilized for the following purposes:

  • Debt Repayment: The company will use some IPO proceeds for payments to repay existing borrowings both within the company and among its subsidiaries.

  • Expansion Plans: New eye care facilities will be built while current facilities will undergo renovations to offer better services across broader markets.

  • General Corporate Purposes: The remaining unreceived funds from this financing will support various general corporate functions that include funding working capital needs as well as initiating strategic developments and covering other enterprise requirements.

Dr Agarwal’s Health care IPO Details

IPO Date

January 29, 2025 to January 31, 2025

Listing Date

Wednesday, February 5, 2025

Face Value

₹1 per share

Price Band

₹382 to ₹402 per share

Lot Size

35 Shares

Total Issue Size

7,53,04,970 shares

(aggregating up to ₹3,027.26 Cr)

Fresh Issue

74,62,686 shares

(aggregating up to ₹ 300.00 Cr)

Offer for Sale

6,78,42,284 shares of ₹1

(aggregating up to ₹2,727.26 Cr)

Issue Type

Book Built Issue IPO

Listing At

BSE, NSE

Shareholding Pre Issue

30,84,17,160 shares

Shareholding Post Issue

31,58,79,846 shares

Dr Agarwal’s Health care IPO Key Dates

IPO Open Date

Wednesday, January 29, 2025

IPO Close Date

Friday, January 31, 2025

Basis of Allotment

Monday, February 3, 2025

Initiation of Refunds

Tuesday, February 4, 2025

Credit of Shares to Demat

Tuesday, February 4, 2025

Listing Date

Wednesday, February 5, 2025

Cut-off time for UPI mandate confirmation

5 PM on January 31, 2025

Dr Agarwal’s Health care IPO Lots allocation

Application

Lots

Shares

Amount

Retail (Min)

1

35

₹14,070

Retail (Max)

14

490

₹1,96,980

S-HNI (Min)

15

525

₹2,11,050

S-HNI (Max)

71

2,485

₹9,98,970

B-HNI (Min)

72

2,520

₹10,13,040

Dr Agarwal’s Health care Limited IPO GMP

Dr Agarwal’s Health care Limited IPO GMP is 164 it means shares traded in the grey market at ₹164 per unit on January 24th, 2025. An IPO pricing analysis exhibits that potential listing shares could cost ₹566 while exceeding the highest possible IPO price range by 40.80 percent.

Financial Performance

As much as GMP can help in providing insight of the general mood within the market at any given time the investors should be wary of the fact that GMP is not a certified measure and at times is manipulated by speculators.

Industry Overview

Fiscal Year 2023-24

  • Operations Revenue: Rs. 319.30 crore

  • At 19% of year on year growth the Operating revenue for FY 2022-23 reached ₹268.10 crores.

  • Profit After Tax (PAT): ₹46.36 crore

The company delivered a 25% earnings gain by earning ₹46.36 crore compared to ₹36.92 crore from last year.

  • EBITDA Margin: Strong operating margins indicative of cost efficiency and operational excellence.

Six Months Ended September 30, 2024 (Unaudited)

  • Total Revenue: ₹204.89 crore

    • Up from ₹164.47 crore during the same period in 2023.

  • Net Income (PAT): ₹28.26 crore

During the six-month period the company reported a PAT of ₹28.26 crore which marked a 17% increase when compared to the preceding year’s corresponding period with ₹24.13 crore in PAT.

  • Operational Efficiency: The company consistently achieves expanding revenue alongside strong profitability in domestic locations and multiple international markets.

Key Revenue Streams
  1. Surgical Services:

    • Significant contribution from high-demand surgeries like cataract and refractive procedures.

  2. Consultation & Diagnostics:

    • Includes initial screenings, eye exams, and advanced diagnostic services.

  3. Optical Products & Pharmaceuticals:

    • Sale of eyeglasses, contact lenses, and proprietary eye-care products adds a supplementary revenue stream.

Growth Projections (Post-IPO)
  • Revenue CAGR Target (2025-2030): The company has set a revenue growth expectation of 20-25% through intensified domestic sales and wider international distribution.

  • Profitability: The company plans to achieve padmashri through operations optimization combined with scale ups.

  • Market Expansion: The company plans to develop its eye care centers across regions with insufficient medical facilities because it wants to strengthen its market footprint.

Conclusion

Potential investors can seize the chance to support Dr. Agarwal’s Health Care Limited IPO because the organization maintains a leading position in eye care while demonstrating established performer status and ambitious growth initiatives. The company demonstrates a robust financial track record which facilitates its promising future success path. Investors need to perform comprehensive research before finalizing their investment in this opportunity while the subscription dates draw nearer.

Shareholders who invest in the Dr Agarwal’s Health Care Limited IPO received access to a maturing eye care business leader in a burgeoning market segment. Investors should base their evaluation on three primary factors which include the company’s exemplary financial metrics along with its advancement approach and growing industry status. Every financial move carries risks so potential investors need to evaluate customer market competition together with regulatory changes and operational obstacles when considering this investment opportunity. To make sound investment choices investors must study the complete prospectus combined with expert financial advice from professional advisors.

FAQ'S

The Dr Agarwal’s Health care Limited IPO is a public offering of equity shares so Investors can become stakeholder in the organization. The funds raised from the IPO will be used to expand the business and debt repayment.

The price band for Dr Agarwal’s Health care IPO is set at Rs.382 to Rs.402 per share.

Minimum 35 shares per lot should be bid by the Investors.

The IPO issue size is ₹3,027.26 crores, which includes:

  • Fresh Issue: ₹300 crores.

  • Offer for Sale (OFS): ₹2,727.26 crores (by existing shareholders).

Opening date of the IPO is January 29, 2025 and the Closing date is set to January 31, 2025.

Interested in learning TRADING? 🚀
Enquire now!